Ipilimumab in a Phase II trial of melanoma patients with brain metastases

Figures & data

Table 1. Patient response and disease control

	Cohort A (n = 51)		Cohort B (n = 21)
	mWHO	irRC	mWHO	irRC
Global disease control	9 (18%, 8- 31)	13 (25%, 14–40)	1 (5%, 0.1–24)	2 (10%, (1–30)
CNS disease control	12 (24%, 13–38)	13 (25%, 14–40)	2 (10%, 1–30)	2 (10%, 1–30)
Non-CNS disease control	14 (27%, 16–42)	17 (33%, 21–48)	1 (5%, 0.1–24)	2 (10%, 1–30)
Global objective response	5 (10%, (3–21)	5 (10%, 3–21)	1 (5%, 0.1–24)	1 (5%, 0.1–24)
CNS objective response	8 (16%, 7–29)	8 (16%, 7–29)	1 (5%, 0.1–24)	1 (5%, 0.1–24)
Non-CNS objective response	7 (14%, 6–26)	7 (14%, 6–26)	1 (5%, 0.1–24)	1 (5%, 0.1–24)

Data are n (%, 95% CI). irRC, immune-related response criteria; mWHO, modified WHO criteria. Reprinted with permission from Margolin et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial. Lancet Oncology 2012; 13:459-65. ©2012; Elsevier.

Figure 1. Overall survival. Reprinted from Lancet Oncology. Volume 13. Kim Margolin, Marc S Ernstoff, Omid Hamid, Donald Lawrence, David McDermott, Igor Puzanov, Jedd D Wolchok, Joseph I Clark, Mario Sznol, Theodore F Logan, Jon Richards, Tracy Michener, Agnes Balogh, Kevin N Heller, F Stephen Hodi. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Pages 459–465. Copyright (2012) with permission from Elsevier.